Effect of D-glucose feeding on mortality induced by sepsis

Sung-Su Kim¹, Yun-Beom Sim¹², Soo-Hyun Park¹, Jae-Ryeong Lee¹, Naveen Sharma¹, and Hong-Won Suh¹*¹

¹Department of Pharmacology, Institute of Natural Medicine, College of Medicine Hallym University, Chuncheon 24252, ²Adult Stem Cell Research Center in Kangstem Biotech, #81, Seoul National University, Seoul 08826, Korea

ABSTRACT Sepsis is the life-threatening response to infection which can lead to tissue damage, organ failure, and death. In the current study, the effect of orally administered D-glucose on the mortality and the blood glucose level induced by D-Galactosamine (GaLN)/lipopolysaccharide (LPS)-induced sepsis was examined in ICR mice. After various amounts of D-glucose (from 1 to 8 g/kg) were orally fed, sepsis was induced by injecting intraperitoneally (i.p.) the mixture of GaLN /LPS. Oral pre-treatment with D-glucose dose-dependently increased the blood glucose level and caused a reduction of sepsis-induced mortality. The oral post-treatment with D-glucose (8 g/kg) up to 3 h caused an elevation of the blood glucose level and protected the mortality observed in sepsis model. However, D-glucose post-treated at 6, 9, or 12 h after sepsis induction did not affect the mortality and the blood glucose level induced by sepsis. Furthermore, the intrathecal (i.t.) pretreatment once with pertussis toxin (PTX; 0.1 µg/5 ml) for 6 days caused a reduction of D-glucose-induced protection of mortality and hyperglycemia. Furthermore, once the hypoglycemic state is continued up to 6 h after sepsis initiated, sepsis-induced mortality could not be reversed by D-glucose fed orally. Based on these findings, it is assumed that the hypoglycemic duration between 3 and 6 h after the sepsis induction may be a critical time of period for the survival. D-glucose-induced protective effect against sepsis-induced mortality appears to be mediated via activating PTX-sensitive G-proteins in the spinal cord. Finally, the production of hyperglycemic state may be critical for the survival against the sepsis-induced mortality.

INTRODUCTION

Sepsis is a severe medical condition caused mainly by the influx of bacteria into the blood [1]. The immune system reacts against the influx of bacteria [2]. In addition, blood clot occurs due to the immune response to the whole body [3]. Blood flow is reduced by blood clotting during, which interferes with blood, nutrients, and oxygen supply and then causes organ damage and hypoperfusion [4]. Sepsis usually alters glucose regulation in the whole body and tissue [5]. The sepsis-induced glucose imbalance is characterized by an initial hyperglycemia followed by a progressive hypoglycemia. The sepsis-induced hyperglycemia may be due to an acute early host response leading to an increase of hepatic gluconeogenesis by activation of the immune response [6,7]. Hyperglycemia may also be developed in septic patients due to insulin clearance leading to a reduction in insulin-mediated glucose uptake [8]. However, during the late phase of sepsis, organ dysfunction is usually occurred [9]. Furthermore, hypotension and hypoglycemia are produced eventually [10]. Hypoglycemia is observed in 16.3% of sepsis patients [11]. Moreover, the exact mechanism of sepsis-induced hypoglycemia is not well elucidated. Some previous studies have reported that hypoglycemia occurred by certain infectious diseases is associated with the limited glycogen stores (e.g., liver disease), impaired gluconeogenesis and...
increased peripheral glucose utilization [6,12-14].

Several lines of evidence have demonstrated that the blood glucose level may be one of the critical factors for rescuing from the dangers of fatality induced by sepsis. In support of the hypothesis, a recent study has demonstrated that ghrelin exerts a protective effect against sepsis-induced lethality by elevating a blood glucose level [15,16]. Although these observations suggest that the blood glucose level control may be one of the important strategies, the clear conclusion on this issue has not been drawn yet. We found recently that the activation of $\alpha_2$-adrenergic receptors located in the spinal cord elevates the blood glucose level [17], and spinally administered clonidine protects against sepsis-induced mortality (unpublished observation). Moreover, in our previous studies we have reported that PTX produces hypoglycemic effect [18-20]. However, the role of the blood glucose level on sepsis-induced mortality has not been characterized yet. Thus, the present study was designed to examine the effects of D-glucose administered orally on mortality and hypoglycemia induced by LPS/GaLN treatment. Furthermore, the role of spinally located PTX-sensitive G-proteins on the pharmacological effect of D-glucose in the regulation of mortality and the blood glucose level in sepsis animal model was examined.

**METHODS**

The experiments were approved by the Hallym University Animal Care and Use Committee (Registration Number: Hallym 2009-05-01). All procedures were conducted in accordance with the ‘Guide for Care and Use of Laboratory Animals’ published by the National Institutes of Health and the ethical guidelines of the International Association for the Study of Pain.

**Experimental animals**

Male ICR mice (M.J. LTD., Seoul, Korea) weighing 23~25 g were used for all the experiments. Animals were housed five per cage in a room maintained at 22±0.5°C with an alternating 12 h light/dark cycle. Food and water were available ad libitum. The animals were allowed to adapt to the laboratory for at least 2 h before testing and were only used once. Experiments were performed during the light phase of the cycle (10:00~17:00 h). These experiments were approved by the University of Hallym Animal Care and Use Committee.

**Oral (p.o.), intraperitoneal (i.p.) and intrathecal (i.t.) administration**

Oral administration was performed with gage in a volume of 500 $\mu$l/25 g body weight. I.p. injection was conducted to anesthetized mice with the volume of 250 $\mu$l. The i.t. administration was performed following the method of Hylden and Wilcox [21,22] using a 30-gauge needle connected to a 25 $\mu$l Hamilton syringe with polyethylene tubing. The i.t. injection volume was 5 $\mu$l, and the injection site was verified by injecting a similar volume of 1% methylene blue solution and determining the distribution of the injected dye in the spinal cord. The dye injected i.t. was distributed both rostrally and caudally but with short distance (about 0.5 cm from the injection site) and no dye was found visually in the brain. The success rate for the injections was consistently found to be over 95% before the experiments were done.

**Blood glucose measurement**

The blood was collected shortly as much as possible with a minimum volume (1 $\mu$l) from the tail-vein. The glucose level was measured using Accu-Chek Performa blood glucose monitoring system (glucometer) (Roche Diagnostics, USA). The blood glucose level was measured at 0.5, 1, 3, 6, 12, 24, 36, 48, 72, 96 h after oral administration with D-glucose (n=10).

**Drugs**

D-Galactosamine, Lipopolysaccharide, and D-glucose were purchased from Sigma Chemical Co. (St. Louis, MO, USA).
Pertussis toxin was purchased from Research Biomedicals (Natick, MA, USA). All drugs used for injection were dissolved in sterile saline (0.9% NaCl with saline or test drugs. The pretreatment time was the same solution). All drugs were prepared just before use. Blood glucose meter, lancing device and strips were purchased from Roche Diagnostics (Accu-Chek Performa, Germany).

**Statistical analysis**

Statistical analysis was carried out by ANOVA (Bonferroni test) for multiple comparisons, by using GraphPad Prism Version 4.0 for Windows (GraphPad Software, San Diego, CA, USA). p-values less than 0.05 were considered to indicate statistical significance. All values were expressed as the mean±S.E.M. In our study, we established the mean blood glucose value of the control group through many experiments under matching conditions. Selected mice of established blood glucose level were then used in replication experiments.

**RESULTS**

**Effect of D-glucose fed orally on sepsis-induced mortality and blood glucose level**

To produce sepsis, the mixture of GaLN (0.6 g/10 ml) and LPS (27 μg/27 μl) was treated i.p. To assess the possible protective effect of D-glucose against sepsis-induced mortality, D-glucose (from 1 to 8 g/kg) was fed orally 30 min prior to GaLN/LPS administration. As shown in Fig. 1A, the mortality rate in GaLN/LPS-induced sepsis group, was 50% at 12 h, 70% at 24 h up to 96 h after GaLN/LPS administration. Although D-glucose at the lowest dose (1 g/kg) used did not affect sepsis-induced mortality, D-glucose at higher amounts (2, 4 and 8 g/kg) reduced mortality rate in a dose-dependent manner. In the sepsis group, the blood glucose level began to fall 1 h and was further down-regulated up to 4 h after sepsis induction as shown in Fig. 1B. D-glucose feeding at the dose of 1 g/kg did not affect the blood glucose level in sepsis group. However, higher amounts (from 2 to 8 g/kg) of D-glucose increased the blood glucose level in a dose-dependent manner. At highest dose (8 g/kg) of D-glucose, the blood glucose level reached at its highest level 30 min and maintained up to 1 h and began to return toward the control level 2 h after oral feeding.

*Fig. 2. Effect of D-glucose post-treated orally on sepsis-induced mortality.* The mice were orally fed with D-glucose (8 g/kg) at 1 (A), 3 (B), 6 (C), 9 (D) and 12 (E) h after i.p. administration with GaLN (0.6 g/10 ml)/LPS (27 μg/27 μl). The mortality rate was counted at 12, 24, 36, 48, 72, 84 and 96 h after GaLN/LPS injection. The number of animals used for each group was 10.
Effect of D-glucose post-treated orally on sepsis-induced mortality and blood glucose level

Since pretreatment of D-glucose was effective in protecting against sepsis-induced mortality, first, D-glucose at a dose of 8 g/kg was post-treated orally at 1, 3, 6, 9, and 12 h after GaLN/LPS administration and its effect on sepsis-induced mortality and blood glucose profile was observed. As revealed in Figs. 2A and 2B, D-glucose post-treated 1 or 3 h after GaLN/LPS administration significantly protected sepsis-induced mortality. However, the protective effect of D-glucose against the sepsis-induced mortality was reduced in the groups post-treated at 6, 9, or 12 h after sepsis induction (Figs. 2C, 2D, and 2E). As revealed in Figs. 3A and 3B, D-glucose post-treated at 1 or 3 h after GaLN/LPS administration was able to increase the blood glucose level in sepsis group. However, 6, 9, or 12 h post-treatment with D-glucose did not affect the blood glucose level in sepsis group (Figs. 3C, 3D, and 3E).

Effect of i.t. pretreatment with pertussis toxin on pharmacological responses of D-glucose in sepsis model

To examine if spinal inhibitory G protein is involved in D-glucose-induced survival, and hyperglycemic effects in sepsis model, the effect of PTX pretreated i.t. on D-glucose-induced hypoglycemic and survival effects in sepsis model was investigated. PTX (0.1 μg/0.5 μl) was pretreated once for 6 days, and D-glucose

Fig. 3. Effect of D-glucose post-treated orally on sepsis-induced hypoglycemia. The mice were orally fed with either D-glucose (8 g/kg) at 1 (A), 3 (B), 6 (C), 9 (D) and 12 (E) h after i.p. administration with GaLN (0.6 g/10 ml)/LPS (27 μg/27 μl). The blood glucose level was measured at various times after GaLN/LPS injection. The number of animals used for each group was 10. (***p<0.001; compared to sepsis group, **p<0.01; compared to sepsis group).

Fig. 4. Effect of i.t. pretreatment with PTX on D-glucose-induced survival and hyperglycemic effects in sepsis model. Mice were pretreated i.t. once with either saline or PTX (0.1 μg/0.5 μl) once for 6 days and D-glucose (8 g/kg) was orally fed 30 min prior to i.p. administration with GaLN (0.6 g/10 ml)/LPS (27 μg/27 μl). The mortality rate (A) was measured at 12, 24, 36, 48, 72, 84 and 96 h after GaLN/LPS injection. The number of animals used for each group was 10 (**p<0.01; compared to Saline+Saline/sepsis group, ***p<0.001; compared to Saline+D-glucose/sepsis group).
(8 g/kg) was administered orally. The i.t. treatment with PTX alone caused a slight hypoglycemic effect as shown in (Fig. 4B). The i.t. pretreatment with PTX attenuated D-glucose-induced hyperglycemic effect and protective effects against mortality produced by sepsis (Figs. 4A and 4B).

**DISCUSSION**

Several studies have previously reported that the hypoglycemia usually occurs during the sepsis [6,12,13,23]. In addition, several lines of evidence have demonstrated that the control of the blood glucose level could be a beneficial strategy to reduce the sepsis-induced lethality [24,25]. Furthermore, even up-regulation of the blood glucose level exerts a protective effect against sepsis-induced mortality. The findings of this study provide evidence of the protective effect against sepsis-induced mortality by counteracting the hyperglycemic effect induced by sepsis (Figs. 4A and 4B).

In general, hypoglycemia is produced during the severe sepsis [14,24,26]. In the present study, we found that the blood glucose level began to fall 1 h and was continuously further down-regulated up to 4 h after sepsis induction. We observed that higher amounts (from 2 to 8 g/kg) of D-glucose cause an elevation of the blood glucose level in a dose-dependent manner. This hyperglycemic effect of D-glucose feeding is still manifested even in the sepsis group post-treated with D-glucose up to 3 h. However, interestingly, oral post-treatment with D-glucose at 6, 9, or 12 h after sepsis induction is not able to cause a hyperglycemia, suggesting that the organs of the body cannot work or perform for normal function, for example, in the regulation of the blood glucose level at 6 h after sepsis induction. This finding demonstrates that the production of hyperglycemia by D-glucose feeding up to 3 h appears to be required for the survival from sepsis-induced mortality. Taken together these observations, we propose a hypothesis that D-glucose feeding may produce the protective effect against sepsis-induced mortality by counteracting the hyperglycemic effect induced by sepsis. The findings observed in the present study are supported by our recent studies.

We found recently that spinal administration of clonidine, an α-2 adrenergic receptor agonist, causes a profound hyperglycemia and shows a protective effect against sepsis-induced mortality in a similar pattern of pharmacological action observed in the present study [unpublished observation]. Furthermore, systemic injection of clonidine also exerts a protective effect against fatality observed in CLP sepsis model [23].

Several studies have previously reported that the hypoglycemia usually occurs during the sepsis [6,12,13,23]. In addition, several lines of evidence have demonstrated that the control of the blood glucose level could be a beneficial strategy to reduce the sepsis-induced lethality [24,25]. Furthermore, even up-regulation of the blood glucose level exerts a protective effect against sepsis-induced mortality. The findings of this study provide evidence of the protective effect against sepsis-induced mortality by counteracting the hyperglycemic effect induced by sepsis (Figs. 4A and 4B).

Some studies have examined the influence of diabetes on sepsis patients. However, the findings are somewhat conflicting. Some of the studies showed the harmful effect of diabetes [27-30], other studies have shown no influence of diabetes [31-34], and some other studies represent protective effect [35-37]. Some clinical studies have shown that hyperglycemia is associated with high mortality in various groups of hospitalized patients [38-40]. Targeting normoglycemia with the use of continuous insulin infusions improves outcomes in a selected group of critically ill patients [41,42]. Our present study indicated that hyperglycemia improves the survival rate in sepsis mouse model. Previous in vitro studies have shown that acute fluctuations of glucose can induce endothelial cell damage and apoptosis [43]. whereas, some clinical studies have also shown a coalition between hypoglycemia and increased mortality among ICU (Intensive Care unit) patients [44,45]. There is insufficient information to determine the optimal blood glucose level in the septic patient [46]. However, whether the maintenance of the blood glucose level just up to the normal level, not to a hyperglycemic state, is able to save the sepsis-induced mortality should be further characterized in the future study.

We found in the present study that spinally pretreated PTX attenuates the hyperglycemic and survival effects induced by D-glucose in sepsis model. This result suggests that inhibitory G-protein located at the spinal cord appear to be involved in the production of hyperglycemia induced by D-glucose-feeding. Several lines of evidence have previously demonstrated that PTX-sensitive G-proteins are involved in the production of hypoglycemia. For example, PTX administered systemically produces a hypoglycemic effect in in vivo study and in vitro study PTX appears to increase the secretion of insulin [47-50]. In addition, we have recently reported that spinal administration with PTX exerts a persistent hypoglycemia in a long-term manner [18,19]. Although the exact mechanism is not fully understood yet, it is speculated that some endogenous factors are activated after D-glucose feeding triggering their action on spinal PTX-sensitive inhibitory G proteins, in turn, leading to produce a hyperglycemia. It is suggested that blocking effect of PTX against the hyperglycemic effect induced by D-glucose appears to be responsible for reversing survival effect induced by D-glucose in sepsis model.

In conclusion, based on the results found in the present study, we propose that the production of a hyperglycemia induced by oral glucose feeding might be a good therapeutic strategy for the protection against sepsis-induced mortality.
ACKNOWLEDGEMENTS

This research was supported by Priority Research Centers (NRF-2009-0094071) Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology and Hallym University Specialization Fund (HRF-S-52).

REFERENCES

1. Levi M, Schouten M, van der Poll T. Sepsis, coagulation, and anti-thrombin: old lessons and new insights. Semin Thromb Hemost. 2008;34:722-746.
2. van Westerloo DJ, Giebelen IA, Florquin S, Daalhuisen J, Bruno MJ, de Vos AF, Tracey KJ, van der Poll T. The cholinergic anti-inflammatory pathway regulates the host response during septic peritonitis. J Infect Dis. 2005;191:2138-2148.
3. Schouten M, Wiersinga WJ, Levi M, van der Poll T. Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol. 2008;83:536-545.
4. Dünser MW, Westphal M. Arginine vasopressin in vasodilatory shock: effects on metabolism and beyond. Curr Opin Anaesthesiol. 2008;21:122-127.
5. Lang CH. Sepsis-induced insulin resistance in rats is mediated by a beta-adrenergic mechanism. Am J Physiol. 1992;263:E703-711.
6. Maitra SR, Wojnar MM, Lang CH. Alterations in tissue glucose uptake during the hyperglycemic and hypoglycemic phases of shock. Shock. 2000;13:379-385.
7. Lang CH, Bagby GJ, Spitzer JJ. Glucose kinetics and body temperature after lethal and nonlethal doses of endotoxin. Am J Physiol. 1985;248:R471-478.
8. Marik PE, Raghavan M. Stress-hyperglycemia, insulin and immunomodulation in sepsis. Intensive Care Med. 2004;30:748-756.
9. Tiruvoipati R, Chieze B, Lewis D, Ong K, Villanueva E, Haji K, Botha J. Sepsis stresshyperglycemia may not be harmful in critically ill patients with sepsis. J Crit Care. 2012;27:153-158.
10. Pulzi Júnior SA, Assunceño MS, Mazza BF, Fernandes Hda S, Jackiu M, Freitas FG, Machado FR. Accuracy of different methods for blood glucose measurement in critically ill patients. Sao Paulo Med J. 2009;127:259-265.
11. Szrama J, Smuszkiewicz P, Trojanowska I. Glycemic profile and effectiveness and safety of insulin therapy in septic patients: is the blood glucose level sufficient? Pol Arch Med Wewn. 2009;119:621-627.
12. Ogetti GN, Akech S, Jemutai J, Boga M, Kivaya E, Fegan G, Maitland K. Hypoglycaemia in severe malaria, clinical associations and relationship to quinine dosage. BMC Infect Dis. 2010;10:334.
13. Clemens MG, Chaudry IH, McDermott PH, Baue AE. Regulation of glucose production from lactate in experimental sepsis. Am J Physiol. 1983;244:R794-800.
14. Miller SI, Wallace RJ Jr, Mushar DM, Septimus EJ, Kohl S, Baughn RE. Hypoglycemia as a manifestation of sepsis. Am J Med. 1980;68:649-654.
15. Chang L, Zhao J, Yang J, Zhang Z, Du J, Tang C. Therapeutic effects of ghrelin on endotoxic shock in rats. Eur J Pharmacol. 2003;473:171-176.
16. Chang L, Du JB, Gao LR, Pang YZ, Tang CS. Effect of ghrelin on septic shock in rats. Acta Pharmacol Sin. 2003;24:45-49.
17. Sim YB, Park SH, Kim SS, Lim SM, Jung JS, Suh HW. Activation of spinal α2 adrenergic receptors induces hyperglycemia in mouse though activating sympathetic outflow. Eur J Pharmacol. 2014;741:316-322.
18. Kim CH, Park SH, Sim YB, Sharma N, Kim SS, Lim SM, Jung JS, Suh HW. Effect of pertussis and cholera toxins administered supraspinally on CA3 hippocampal neuronal cell death and the blood glucose level induced by kainic acid in mice. Neurosci Res. 2014;89:31-36.
19. Sim YB, Park SH, Kim SS, Lim SM, Jung JS, Lee JK, Suh HW. Pertussis toxin administered spinally induces a hypoglycemic effect on normal and diabetic mice. Pharmacology. 2014:94:29-40.
20. Suh HW, Sim YB, Choi YS, Song DK, Kim YH. Multiplicative interaction between intrathecally and intracerebroventricularly administered morphine for antinociception in the mouse: effects of spinally and supraspinally injected 3-isobutyl-1-methylxanthine, cholera toxin, and pertussis toxin. Gen Pharmacol. 1995;26:1597-1602.
21. Hyliden JL, Wilcox GL. Intrathecal substance P elicits a caudally-directed biting and scratching behavior in mice. Brain Res. 1981;217:212-215.
22. Hyliden JL, Wilcox GL. Intrathecal morphine in mice: a new technique. Eur J Pharmacol. 1980;67:313-316.
23. Polito A, Brouland JP, Porcher R, Sonneville R, Siami S, Stevens RD, Guidoux C, Maxime V, de la Grandmaison GL, Chrétien FC, Gray F, Annane D, Sharshar T. Hyperglycaemia and apoptosis of microglial cells in human septic shock. Crit Care. 2011;15:R131.
24. Hirasawa H, Oda S, Nakamura M. Blood glucose control in patients with severe sepsis and septic shock. World J Gastroenterol. 2009;15:4132-4136.
25. Thompson BT. Glucose control in sepsis. Clin Chest Med. 2008;29:713-720.
26. Igaki N, Matsuda T, Hirotta Y, Kawaguchi T, Tamada F, Goto T. Streptococcal toxic shock syndrome presenting with spontaneous hypoglycemia in a chronic hemodialysis patient: pathophysiological mechanisms. Intern Med. 2003;42:421-423.
27. Kornum JB, Thomsen RW, Riis A, Lervang HH, Schönheyder HC, Sørensen HT. Type 2 diabetes and pneumonia outcomes: a population-based cohort study. Diabetes Care. 2007;30:2251-2257.
28. Benfield T, Jensen JS, Nordestgaard BG. Influence of diabetes and hyperglycaemia on infectious disease hospitalisation and outcome. Diabetologia. 2007;50:549-554.
29. Thomsen RW, Hundborg HH, Lervang HH, Johnsen SP, Schönheyder HC, Sørensen HT. Diabetes mellitus as a risk and prognostic factor for community-acquired bacteremia due to enterobacteria: a 10-year, population-based study among adults. Clin Infect Dis. 2005;40:628-631.
30. Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care. 2003;26:510-513.
31. Vincent JL, Preiser JC, Sprung CL, Moreno R, Sakr Y. Insulin-treated diabetes is not associated with increased mortality in critically ill patients. Crit Care. 2010;14:R12.
32. Stegenga ME, Vincent JL, Vail GM, Xie J, Haney DJ, Williams MD, Bernard GR, van der Poll T. Diabetes does not alter mortality or
hemostatic and inflammatory responses in patients with severe sepsis. Crit Care Med. 2010;38:539-545.
33. Tsai CL, Lee CC, Ma MH, Fang CC, Chen SY, Chen WJ, Chang SC, Mehta SH. Impact of diabetes on mortality among patients with community-acquired bacteremia. J Infect. 2007;55:27-33.
34. McAlister FA, Majumdar SR, Blitz S, Rowe BH, Romney J, Marrie TJ. The relation between hyperglycemia and outcomes in 2,471 patients admitted to the hospital with community-acquired pneumonia. Diabetes Care. 2005;28:810-815.
35. Graham BB, Keniston A, Gajic O, Trillo Alvarez CA, Medvedev S, Douglas IS. Diabetes mellitus does not adversely affect outcomes from a critical illness. Crit Care Med. 2010;38:16-24.
36. Esper AM, Moss M, Martin GS. The effect of diabetes mellitus on organ dysfunction with sepsis: an epidemiological study. Crit Care. 2009;13:R18.
37. Thomsen RW, Hundborg HH, Lervang HH, Johnsen SP, Sørensen HT, Schønheyder HC. Diabetes and outcome of community-acquired pneumococcal bacteremia: a 10-year population-based cohort study. Diabetes Care. 2004;27:70-76.
38. Ali NA, O’Brien JM Jr, Blum W, Byrd JC, Klisovic RB, Marcucci G, Phillips G, Marsh CB, Lemeshow S, Grever MR. Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality. Cancer. 2007;110:96-102.
39. Weiser MA, Cabanillas ME, Konopleva M, Thomas DA, Pierce SA, Escalante CP, Kantarjian HM, O’Brien SM. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. Cancer. 2004;100:1179-1185.
40. Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendic S, Rydén L, Malmberg K. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet. 2002;359:2140-2144.
41. Van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, Van Wijngaerden E, Bobbaers H, Bouillon R. Intensive insulin therapy in the medical ICU. N Engl J Med. 2006;354:449-461.
42. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345:1359-1367.
43. Risso A, Mercuri F, Quagliaro L, Damante G, Ceriello A. Intermittent high glucose enhances apoptosis in human umbilical vein endothelial cells in culture. Am J Physiol Endocrinol Metab. 2001;281:E924-930.
44. Pinto DS, Skolnick AH, Kirtane AJ, Murphy SA, Barron HV, Giugliano RP, Cannon CP, Braunwald E, Gibson CM; TIMI Study Group. U-shaped relationship of blood glucose with adverse outcomes among patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2005;46:178-180.
45. Mendoza A, Kim YN, Chernoff A. Hypoglycemia in hospitalized adult patients without diabetes. Endocr Pract. 2005;11:91-96.
46. Griesdale DE, de Souza RJ, van Dam RM, Heyland DK, Cook DJ, Malhotra A, Dhaliwal R, Henderson WR, Chittock DR, Finner S, Talmor D. Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. CMAJ. 2009;180:821-827.
47. Komatsu M, McDermott AM, Gillison SL, Sharp GW. Time course of action of pertussis toxin to block the inhibition of stimulated insulin release by norepinephrine. Endocrinology. 1995;136:1857-1863.
48. García Hermida O, Fontela T, Ghiglione M, Uttenthal LO. Effect of pertussis pretreatment on plasma glucose and insulin responses to lithium in rats. Br J Pharmacol. 1991;103:1309-1312.
49. Khalaf IJ, Taylor KW. Pertussis toxin reverses the inhibition of insulin secretion caused by [Arg8]vasopressin in rat pancreatic islets. FEBS Lett. 1988;231:148-150.
50. Toyota T, Kai Y, Kakizaki M, Sakai A, Goto Y, Yajima M, Ui M. Effects of islet-activating protein (IAP) on blood glucose and plasma insulin in healthy volunteers (phase 1 studies). Tohoku J Exp Med. 1980;130:105-116.